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Abstract
Background: Chronic kidney disease (CKD) is a worldwide public health problem and more so in India. With
limited availability and high cost of therapy, barely 10 % of patients with incident end stage renal disease (ESRD)
cases get treatment in India. Therefore, all possible efforts should be made to retard progression of CKD. This article
reviews the role of low protein diet (LPD) in management of CKD subjects and suggests how to apply it in clinical
practice.
Discussion: The role of LPD in retarding progression of CKD is well established in animal experimental studies.
However, its role in human subjects with CKD is perceived to be controversial based on the modification of diet
in renal disease (MDRD) study. We believe that beneficial effect of LPD could not be appreciated due to shorter
duration of follow-up in the MDRD study. Had the study been continued longer, it may have been possible to
appreciate beneficial effect of LPD. It is our contention that in all cases of CKD that are slowly progressive, LPD
can significantly retard progression of CKD and delay the need for renal replacement therapy (RRT). To be able
to apply LPD for a long period, it is important to prescribe LPD at earlier stages (1,2,3) of CKD and not at late
stage as recommended by KDIGO guidelines. Many clinicians are concerned about worsening nutritional status
and hence reluctant to prescribe LPD. This actually is true for patients with advanced CKD in whom there is
spontaneous decrease in calorie and protein intake. In our experience, nutritional status of patients in early stages
(1,2,3) of CKD is as good as that of healthy subjects. Prescribing LPD at an early stage is unlikely to worsen status.
Summary: The role of LPD in retarding progression of CKD is well established in animal experimental studies. Even
in human subjects, there is enough evidence to suggest that LPD retards progression of CKD in carefully selected
subjects. It should be prescribed to those with good appetite, good nutritional status and a slowly progressive CKD at an
early stage (stage 1,2,3). It may also be prescribed at stage 4 & 5 of CKD if the appetite and nutritional status are good.
Keywords: Low protein diet, Chronic kidney disease, Pre-ESRD, Very low protein diet, Ketoanalogues, Practical aspects
Background
Chronic kidney disease (CKD) is a worldwide public
health problem. This problem is even more in socioeco-
nomically deprived countries because lower income and
social deprivation are associated with higher incidence
of macroalbuminuria, reduced GFR, progressive kidney
function loss and end stage renal disease (ESRD) [1–3].
Therefore, the problem of CKD is likely to be higher in
India and other socioeconomically deprived countries
than in the affluent western countries. The problem of
CKD in India is likely to be higher also because of rising
burden of diabetes and hypertension [4, 5].
In the absence of a Govt. set up national renal registry,
the exact disease burden of CKD and ESRD in the
Indian population is unknown. However, an Indian
population-based study determined the crude ESRD
incidence rates at 151 per million population [6]. This
however seems to be an underestimate for reasons cited
above.
With limited availability and high cost of therapy,
barely 10 % of patients with incident ESRD cases get
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treatment in India [7]. Therefore, major emphasis should
be on early detection of CKD and application of all
possible measures to retard progression of CKD. The
important role of blood pressure control in retarding
progression of CKD is well established. However, the
role of low protein diet (LPD) remains controversial.
This article reviews the role of LPD in management of




Studies in animals have clearly shown that high protein
intake relative to functioning renal mass contributes to
progressive decline in kidney function [8–12]. Based on
observations in animal experimental studies, Brenner et
al. [13] proposed a hypothesis. They proposed that when
the functioning renal mass is reduced, hemodynamic
changes develop in the remnant nephrons. These changes,
which partially offset the loss of function that would
result, are compensatory or adaptive. It is these adap-
tive changes that contribute to progressive deterior-
ation in renal function (Fig. 1). Restricting dietary
protein early in the course of renal disease can
minimize the adaptive changes and thereby retard
progressive deterioration in renal function.
With Brenner’s hypothesis, there was a resurgence of
interest in LPD. Before the hypothesis, LPD was prac-
ticed as suggested by Giordano and Giovannetti [14]
mainly to mitigate uremic symptoms in advanced CKD.
After the hypothesis, the interest was to study the effect
of LPD in retarding progression of CKD in human
subjects. These studies did suggest a beneficial effect
[15, 16]. However, there were two major limitations of
these studies: 1) they used creatinine as a marker of kid-
ney function (which we now know is not an ideal
marker of kidney function) and 2) they used 1/cre-
atinine vs. time plot with patient as his own control,
as proposed by Mitch et al. [17] to monitor the rate
of progression of CKD, which Shah and Levey [18]
have shown is not appropriate. The use of these in-
appropriate parameters cast doubt on interpretations
of the earlier studies of LPD.
The limitations of earlier studies were eliminated in
the modification of Diet in Renal Disease (MDRD) Study
[19] which used renal clearance of Iothalamate to assess
the GFR and GFR vs. time plot to monitor rate of de-
cline in renal function in comparable groups of patients.
In this study, 585 patients were included in study A &
255 patients were included in study B. Study A included
patients with glomerular filtration rate (GFR) 25 to
55 ml/min and they were prescribed usual (1.3 gm/
kg/day) or low protein (0.58 gm/kg/day). Study B
included patients with GFR 13 to 24 ml/min. and
they were prescribed low protein diet (0.58 gm/kg/
day) or very low protein diet (0.28gm/kg/day) supple-
mented with ketoanalogs (KA). In both Study A & B,
diabetics were excluded. The conclusion of the study
was that that there was some slowing in the rate of
decline in GFR in study A and no significant differ-
ence in the rate of decline in GFR in study B.
Around the time, MDRD study was published, we
were looking at dietary protein intake in our stable
patients with CKD stage 4 and 5. We observed that most
of our subjects were predominantly vegetarians and their
mean ± 1 SD protein intake was low (0.65 ± 0.15) gm/kg/
day even when not prescribed any restriction [20]. A
similar observation was made by Ikizler et. al. [21]. Con-
sidering such low protein intake, we thought that there
was limited scope for prescribing any dietary protein
restriction to Indian subjects with CKD, particularly
vegetarians even if there was any benefit of LPD.
In 2002, Kher [22], in a nephrology forum discussed
about huge burden of ESRD in India and limited avail-
ability and affordability of RRT. This prompted us to re-
view the role of LPD in preventing and retarding
progression of CKD to ESRD.
We reviewed the MDRD study and realized that its
major limitation was the duration of the study. In any
slowly progressive condition, a longer follow-up is re-
quired to appreciate the effect of any therapeutic inter-
vention. For example, in the Diabetes Control and
Complication trial (DCCT), there was no difference in
development of microalbuminuria or clinical albumin-
uria at 3 to 4 years in the groups treated conventionally
or with intensive insulin therapy. However, on long-term
follow-up, a significantly lower percentage of patients
Fig. 1 Hypothesis proposed by Brenner et al. [13]. Unrestricted
protein intake in the face of decreased number of functioning
nephrons leads to increase in glomerular capillary flow and
glomerular capillary pressure. These hemodynamic changes
lead to glomerulosclerosis. This results in further reduction in
functioning nephrons and setting up of a vicious cycle which
culminates in end stage renal disease
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developed microalbuminuria and clinical albuminuria in
the group treated intensively with insulin [23].
In the MDRD study A patients, there was a rapid
decline in kidney function in subjects with low protein
diet for the first 4 months. This was hemodynamically
mediated. After 4 months the rate of decline in kidney
functions in patients with protein restriction was slower
than in those on usual protein diet. Had the study been
continued further, it would have been possible to appre-
ciate beneficial effect of dietary protein restriction [24].
Figure 2 shows potential benefit of dietary protein
restriction on longer follow-up.
Even otherwise, secondary analysis of the MDRD
study suggested that dietary protein restriction was
beneficial [25, 26].
Observing that a longer period of treatment can show
beneficial effect of LPD in subjects with CKD and that
secondary analysis of MDRD study did show beneficial
effect of LPD, we realized that it is important to advise
dietary protein restriction at an early stage of CKD and
to those with slowly progressive CKD. Also some Indian
studies reported beneficial effect of LPD.
Prakash et al [27] conducted a randomized. Double-
blind, placebo controlled trial to evaluate efficacy of
VLPD supplemented with KA in patients with CKD.
Thirty-four patients were randomized to 2 comparable
groups in terms of age, sex distribution, etiology of
CKD, blood pressure control, use of angiotensin convert-
ing enzyme inhibitors, GFR and body mass index (BMI).
Subjects randomly received either 0.6 gm/kg/day protein
plus placebo (n = 16) or 0.3 gm/kg/day protein plus 1
tablet/5 kg of KA (Ketosteril;Fresenius Kabi, Germany)
for 9 months. The mean GFR at baseline in the KA
group and control group was 28.1 + 8.8 and 28.6 +
17.6 ml/min/1.73 m2 respectively. At the end of the
study it was 27.6 + 10.1 and 22.5 + 15.9 ml/min/1.73 m2
respectively. Thus there was a significant drop in GFR in
the control group compared to KA group. In both
groups there was no significant change in the BMI after
the study.
Subhramanyam et al. [28] assessed the effect of low
protein diet in 178 adult patients with CKD Stages 3–5
(predialysis) for 1 year. Based on affordability of costly
KA, Low-protein diet (0.6 g/kg) supplemented with one
KA tablet for every 10 kg body weight (BW) was
prescribed to 122 patients (sLPD group) and very low
protein diet supplemented with one KA tablet for every
5 kg BW was prescribed to 56 patients s(VLPD group).
In the sLPD group, the blood urea level decreased from
85.38 ± 4.45 to 76.90 ± 42.90 mg/dl (p < 0.05) after
12 months. The 24-h urinary creatinine clearance (CrCl)
improved from 24.59 ± 16.13 ml/min to 29.45 ±
28.16 mL/min after 12 months. In the sVLPD group, the
blood urea level which was 98.38 ± 42.97 mg/dl at
baseline marginally increased to 102.74 ± 45.98 mg/dL
(p > 0.05) at the end of 1 year. The CrCl improved from
17.25 ± 9.25 ml/min at baseline to 18.24 ± 12.12 mL/min
at the end of 1 year, but this increase was not statistically
significant. There was a decrease in urinary protein
excretion and improvement in metabolic status, and
nutrition in both groups. In this study it is difficult to
understand improvement in CrCl and better outcome
with sLPD compared to sVLPD.
We also studied efficacy and safety of KA supple-
mented very low protein diet in patients with CKD. The
study included 29 stable stage V (non-diabetic) patients
with slowly progressive CKD. Fourteen agreed to treat-
ment with KA (treatment group) and 15 did not agree
(control group). The patients in both groups were
comparable as regards age, sex, dietary habits, degree of
renal dysfunction and degree of proteinuria. Patients in
the treatment group were prescribed 0.3 g/kg/day mixed
protein supplemented with KA (ketosteril 1 tablet/5 kg
body weight) while patients in the control group were
allowed to continue regular diet. Renal function was
monitored from 24 h urinary creatinine clearance and
protein intake was monitored from urea nitrogen ap-
pearance (UNA) i.e. 6.25(24 h urinary urea nitrogen +
0.031xweight in kg). All were followed monthly for
6 months. The rate of decline in creatinine clearance
was 0.09 ml/min/month in the treatment group while it
was 0.3 ml/min/month in the control group (Fig. 3).
The concern about prescribing dietary protein restric-
tion is that it is difficult to follow and that it increases
the risk of malnutrition. As regards, difficulty in follow-
ing LPD, one needs a good dietician who can help
patients adjust to protein restricted diet. We also con-
duct a kidney workshop every week educating patients
Fig. 2 A longer duration of study required to appreciate beneficial
effect of LPD. The graph shows rate of decline in GFR in patients on
usual protein (1.3 g/kg/day) and in those on low protein (0.58 g/kg/dy).
Because of initial rapid decline in GFR which was hemodynamically
mediated, although subsequent rate of decline was slower in subjects
prescribed a low protein diet (solid line), the absolute decrease in GFR
was not significantly different when compared to subjects allowed
usual protein diet over a follow-up period of 36 months (F36). If the
study had been continued further, it would have been possible to see
the beneficial effect of low protein diet compared to usual protein
diet as shown by extrapolated lines
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with CKD. In the workshop we educate patients about
progressive nature of CKD and limited treatment
options when kidneys fail. This education also helps
patients work hard to follow every possible measure
including dietary modification to retard progression of
CKD.
The risk of malnutrition is not true if LPD is instituted
at an early stage when the appetite and nutritional status
is good. We looked at body-mass index [BMI] of 560
patients in different stages of CKD (Fig. 4). The mean
BMI (kg/m2) of patients with stage 1 CKD was 32; stage
2 CKD, 28; stage 3 CKD, 28; stage 4 CKD, 25 and stage
5 CKD, 22.5. This shows that nutritional status of pa-
tients as judged from BMI is good until stage 3 of CKD
and tends to drop thereafter. This has important clinical
implication. Dietary modification should be prescribed
in early stages of CKD and not in late stage (stage 4 & 5)
as practiced by many and suggested by KDIGO [29].
In summary there is enough evidence to suggest
that LPD retards the rate of progression of CKD. It
should be implemented at an early stage of CKD and
in those with slowly progressive disease to be able to
appreciate its beneficial effects. We do not agree with
KDIGO recommendations of lowering protein intake
to 0.8 g/kg/day only when GFR <30 ml/min/1.73 m2
(GFR categories G4-G5), In our opinion, LPD (0.6 to
0.8 g/kg/day) should be prescribed to those with
slowly progressive CKD at an early stage (1, 2 and 3)
and KA supplemented very low protein diet should
be prescribed to those with good appetite, good nutri-
tional status and slowly progressive CKD at an ad-
vanced stage (4 and 5).
Practical aspects of LPD
At the outset, one needs to decide who should be sub-
jected to LPD. Not all patients benefit from LPD. In fact,
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Fig. 3 Efficacy of VLPD + KA on rate of decline in creatinine clearance in patients with slowly progressive CKD. The slope of creatinine clearance
vs. time was −0.09 ml/min/month in patients prescribed 0.3 g/kg/day mixed protein supplemented with ketoanalogues (treatment group) while
it was −0.3 in the patients allowed to continue regular diet (control group). One can notice that in the treatment group there was an initial rapid
drop in creatinine clearance (possibly hemodynamically mediated). Thereafter, creatinine clearance stabilized. On the other hand, there was a
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Fig. 4 Body-mass index (kg/m2) of patients in different stages of CKD. The nutritional status of patients remains good until stage 3 of CKD. It
tends to decline only in the late stages of CKD (stage 4 & 5)



























Fig. 5 Example of a vegetarian patient with stable renal function without dietary modification. Serial weight and creatinine values in a 62 years
old vegetarian female with no edema and non-proteinuric kidney disease without any dietary modification prescribed. The serum creatinine has
remained stable for last 12 years
Table 1 A Standard North Indian & South Indian Cuisine Plan for LPD (0.6gm/kg/day) for a 60 kg patient
North Indian menu South Indian menu
B’fast: Tea 1 Cup (Cow Milk 50 ml) Coffee 1 Cup (Cow Milk 50 ml)
Cereal 30 gm (e.g. Vegetable Stuffed Wheat Paratha1) Cereal 30 gm (e.g. Idli9)
Vegetable 50 gm Lentil 15 gm
Yoghurt (Cow Milk based) 50 gm Vegetable 100 gm (e.g. Vegetable Rasam10)
Mid Morning: Fruit 1 (100 gm) Fruit 1 (100 gm)
Lunch: Cereal + Starch Flour 150 gm (e.g. Wheat Chapati 2 + Boil Rice3) Cereal 90 gm (e.g. Boil Rice)
Vegetable 200 gm (e.g. Gobi Aloo Vegetable4) Lentil 30 gm (e.g. Vegetable Sambhar11)
Lentil 15 gm (e.g. Chole Masala5) Vegetable 200 gm (e.g. Bean Aloo Vegetable12)
Yoghurt (Cow Milk based) 50 gm Yoghurt (Cow Milk based) 50 gm
Teatime: Tea 1 Cup (Cow Milk 50 ml) Coffee 1 Cup (Cow Milk 50 ml)
Starch Vegetable 100 gm (e.g. Aloo Tikki6) Cereal 30 gm (e.g. Dosa13)
Mid-Evening: Fruit 1 (100 gm) Fruit 1 (100 gm)
Dinner: Cereal + Starch Flour 150 gm (e.g. Wheat Chapati + Boil Rice) Cereal 90 gm (e.g. Boil Rice)
Vegetable 200 gm (e.g. Methi Aloo Vegetable7) Lentil 30 gm (e.g. Dal Rasam14)
Lentil 15 gm (e.g. Chana Masala8) Vegetable 150 gm (e.g. Brinjal Potato Vegetable15)
Yoghurt (Cow Milk based) 50 gm Yoghurt (Cow Milk based) 50 gm
Note: To use Oil and Ghee 6 tsp/day
See - Legend Table
English names: 1 = Indian Bread Stuffed with vegetables, 2 = Indian Bread, 3 = Steam Rice, 4 = Cauliflower Potato Vegetable, 5 = Chickpeas Vegetable, 6 = Potato
Cutlet 7 = Fenugreek Potato Vegetable, 8 = Bengal Gram Vegetable, 9 = Indian Savory Steamed Dumpling, 10 = Vegetable Soup, 11 = Lentil + Vegetable
Soup, 12 = French Potato Vegetable, 13 = Indian Savory Pancake, 14 = Lentil + Vegetable Soup, 15 = Brinjal Potato Vegetable
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in some it may prove to be detrimental. Therefore, pre-
scription of dietary protein will vary from case to case.
In practice, one does come across patients with
CKD who maintain stable renal function without any
dietary modification. Such patients need not be
prescribed any LPD. Figure 5 shows an example of a
patient (vegetarian) who has maintained stable renal
function and stable nutritional status for more than
10 years. Her current weight is 71 kg (62 kg 12 years
back) and serum albumin is 4 g/dl. Intermittent as-
sessment of her protein intake from urea nitrogen ap-
pearance (UNA) has shown her protein intake to be
0.6 to 0.8 g/kg/day without any prescription of LPD.
It is likely that this low protein intake has helped her
remain very stable. One may argue that creatinine is
not a good marker of renal function. That is true only
Fig. 6 North Indian cuisine
Fig. 7 South Indian cuisine
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in the context of an edematous patient or a patient
changing diet and losing muscle mass. In absence of
that, as in our case, creatinine is still the simplest and
reliable marker of kidney function.
In patients with slowly progressive CKD at an early
stage (1,2,3) if protein intake is > 0.8 g/kg/day, we pre-
scribe a LPD. Table 1 and Figs. 6 and 7 show standard
north and south Indian cuisine plan providing 33 kcal/
kg/day and 0.6 g/kg/day protein for a patient weighing
60 kg.
If the kidney disease is rapidly progressive, LPD is not
of much help. Figure 8 shows an example of a case of
rapidly worsening kidney function. This 52 years old

































Fig. 9 Example to show beneficial effect of LPD with slowly progressive CKD. Serial weight and creatinine values in a 83 years old physician who was


































Fig. 8 Example to show lack of benefit of dietary modification when kidney function is deteriorating rapidly. Serial weight and creatinine values
in a 52 years old male with hypertensive nephrosclerosis. He maintained stable creatinine for many years on regular diet. He then resorted to
alternative therapy. Following that, his creatinine started rising rapidly. Very low protein diet supplemented with KA was started but had no
significant impact
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He was stable for many years on regular diet. He then
resorted to alternative therapy. Following that, his renal
function started deteriorating. Very low protein diet
(0.3 g/kg/day) supplemented with 13 tablets of KA (for
his edema free weight of 63 kg) was prescribed when
creatinine began to rise rapidly. During this period, his
24 h urinary urea nitrogen was 3.17 g (0.47 g contrib-
uted by 13 tablets of KA). Adding extra-renal nitro-
gen loss (assumed to be 0.031 g/kg) his total nitrogen
loss came to 5.12 g/day. Thus his protein intake was
32 g/day (0.48 g/kg/day). This protein restriction
however had no significant impact on the rate of
decline in his kidney function. He eventually under-
went preemptive kidney transplant with mother as
donor.
When kidney disease is slowly progressive, LPD is
likely to be helpful. Figure 9 shows example of a 83 years
old physician who was detected to have slowly progres-
sive CKD in 2006. He was prescribed VLPD (Table 2
and Fig. 10) supplemented with KA (1 tablet/5 kg). He
has maintained a very stable creatinine and nutritional
status for 10 years. His current weight is 65 kg, BMI
23.35 kg/m2 and serum albumin 4.6 g/dl. We are not
sure if he would have remained stable without LPD
which was advised only when he had 3 consecutive
values of creatinine showing a rising trend. His protein
intake (dietary plus supplemented KA) as judged from
UNA remains about 0.48 to 0.5 g/kg/day.
In any case, before advising dietary protein restriction,
it is important to ensure that the appetite is normal. If
the appetite is poor, there is no point advising LPD.
Often, out of fear of dialysis, patients may not complain
of poor appetite. In these cases, if there is worsening
nutritional status as judged by weight loss, LPD should
not be advised.
Conclusions
The role of LPD in retarding progression of CKD is well
established in animal experimental studies. Even in
human subjects, there is enough evidence to suggest that
LPD retards progression of CKD in carefully selected
subjects. It should be prescribed to those with slowly
progressive CKD at an early stage (stage 1–3) when the
appetite and nutritional status are good, rather than at
late stage (stage 4 & 5). It can be prescribed even at late
stages of CKD if the appetite and nutritional status are
Table 2 A Standard VLPD (0.3gm/kg/day) plan for a Patient
weighing 70 kg
B’fast: Tea 1 Cup (Cow Milk 25 ml)
Cereal 30 gm (e.g. Poha1)
Mid Morning: Fruit 1 (100 gm)
Lunch: Cereal + Starch Flour 120 gm (e.g. Rice Flour 60 gm +
Arrowroot Flour 60 gm2) Vegetable 300 gm (e.g.
Suran Vegetable3 + Dudhi Aloo Vegetable4)
Lentil 10 gm (e.g. Thin Dal5) OR Yoghurt (Cow Milk
based) 50 gm
Teatime: Fruit 1 (100 gm)
Dinner: Cereal + Starch Flour 120 gm (e.g. Rice Flour 60 gm +
Arrowroot 60 gm)
Vegetable 300 gm (e.g. Arbi Vegetable6+ Beans
Potato Vegetable7)
Lentil 10 gm (e.g. Thin Dal) OR Yoghurt (Cow Milk
based) 50 gm
Note: To use Oil and Ghee 6 tsp/day
English names: 1 = Indian Savour – Rice Flakes Based, 2 = Indian Bread,
3 = Root Vegetable, 4 = Bottle Gourd and Potato Vegetable, 5 = Lentil,
6 = Root Vegetable, 7 = Beans and Potato Vegetable
Fig. 10 Sample menu of VLPD
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good. It should not be prescribed to those with poor
appetite and weight loss.
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